Diabetes Prevention Program (METFIT) in Reducing Insulin Resistance in Stage I-III Breast Cancer Survivors
NCT ID: NCT04560439
Last Updated: 2022-06-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
NA
INTERVENTIONAL
2022-06-15
2023-06-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Insulin Sensitivity After Breast Cancer
NCT05010356
Metabolic Impact of Intermittent Fasting in Early Type 2 Diabetes
NCT05717127
Pharmacokinetics of Leptin Administration During Fasting
NCT00140205
The Effects of Calorie Restriction With or Without Metformin on Weight and Insulin Resistance
NCT00134290
Intermittent Fasting for the Treatment of Type 2 Diabetes Mellitus
NCT05860413
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. To evaluate the feasibility of the METFIT Program - a 6-month modified Diabetes Prevention Program (DPP)-based lifestyle modification intervention that utilizes intermittent fasting (IF) aimed at reducing insulin resistance (IR) in insulin resistant breast cancer survivors.
SECONDARY OBJECTIVE:
I. To estimate an effect size of the effectiveness of the METFIT Program in reducing IR in insulin resistant breast cancer survivors.
OUTLINE:
Patients undergo METFIT program for 16 sessions over 6 months.
After completion of study treatment, patients are followed up for 40 days.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment (METFIT program)
Patients undergo METFIT program for 16 sessions over 6 months.
Dietary Intervention
Undergo METFIT program
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dietary Intervention
Undergo METFIT program
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Demonstrated at least a 10% weight gain since being diagnosed with breast cancer
* Demonstrated IR by having a Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) score of \>= 2.0
* Demonstrated IR manifested by meeting criteria for metabolic equivalent (MetS) as defined by modified criteria of the National Cholesterol Education Program Adult Treatment Panel (NCEP ATP III) (2005 version) and the World Health Organization (WHO) which includes:
* Dysregulation of glucose homeostasis demonstrated by a glycosylated hemoglobin (HbA1c) \>= 6.5%; OR fasting plasma glucose \>= 126 mg/dl (7.0 mmol/L) OR random plasma glucose \>= 200 mg/dL (11.1 mmol/L)
* Plus two of any of the following:
* Waist circumference in men \>= 40 inches and in women \>= 35 inches
* Elevated triglycerides \>= 150 mg/dL
* Low high-density lipoprotein (HDL) cholesterol in men \< 40 mg /dL and in women \< 50 mg/dL or taking statin medication
* Elevated blood pressure defined by a systolic pressure \>= 130 of a diastolic pressure \>= 85 mm Hg or taking anti-hypertensive medication
* Elevated fasting glucose \>= 110 mg/dL
* Non-smoker (last use 6 months prior to enrollment into the study)
* Documented informed consent of the participant and/or legally authorized representative
* Willingness to make substantial changes in their dietary and physical activity behavior
* Willingness to attend at 70% of the intervention sessions and 100% of the blood draws
* The effects of IF on the developing fetus of breast cancer survivors are unknown. For this reason, women of child bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for six months following duration of study participation. Should a woman become pregnant or suspect that she is pregnant while participating in the trial, should inform her treating physician immediately
* Willingness to weigh themselves weekly
* Willingness to wear a subcutaneous continuous glucose monitor
* Access to an electronic virtual teleconferencing device and capacity to utilize electronic teleconference technology
Exclusion Criteria
* Type 2 diabetes
* History of myocardial infarction or congestive heart failure within the previous 12 months prior to being screened for participation in the study
* Cardiovascular, respiratory or musculoskeletal disease or joint problems that preclude moderate physical activity
* Unstable cardiac disease as defined by one of the following:
* Cardiac events such as myocardial infarction (MI) within the past 6 months
* New York Heart Association (NYHA) heart failure class III-IV
* Uncontrolled atrial fibrillation or hypertension
* History of vascular disease (e.g. deep vein thrombosis, stroke) within six months of starting the intervention
* Clinically significant uncontrolled illness
* Women who are pregnant or breastfeeding
* Any other condition (including psychosocial condition) that would, in the investigator's judgment, contraindicates the patient's participation in the clinical study due to safety concerns with clinical study procedures
* Any other condition that would confound study results
* Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)
18 Years
75 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
City of Hope Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Raynald Samoa
Role: PRINCIPAL_INVESTIGATOR
City of Hope Medical Center
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2020-04551
Identifier Type: REGISTRY
Identifier Source: secondary_id
19447
Identifier Type: OTHER
Identifier Source: secondary_id
19447
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.